Virtus Logo
Contact

Our Founders

Virtus’s Founders have worked together since 2001 in various academic and commercial settings.

Professor Sebastian Johnston and Dr Mike Edwards

Professor Sebastian Johnston and Dr Michael Edwards
Professor Sebastian Johnston and Dr Michael Edwards

Our experience working with VirTus was terrific. They were easy to interact with, collaborative, and provided helpful advice and information at every turn throughout the clinical trial.

Brenton Scott, President and COO, Pulmotect, Inc.

Professor Sebastian Johnston and Dr Mike Edwards

Prof Sebastian Johnston has been performing respiratory virus-related research including human virus challenge studies in asthma for more than 30 years and is the only investigator worldwide to have performed such studies in people with COPD. He has to date successfully infected over 450 subjects with rhinovirus, including over 50 subjects with COPD and over 100 subjects with asthma, including moderately severe asthma and asthma that is not well controlled at time of challenge.

Dr Michael Edwards is a scientist that has worked in a variety of pre-clinical in vitro, in vivo and ex vivo models for over 18 years. As an academic, Michael studied the innate immune responses to respiratory viruses including the identification of new targets for drug discovery purposes. He has also assisted Sebastian in the development of rhinovirus challenge models.

Together, they now combine their joint expertise in respiratory medicine to deliver a commercial service that will greatly aid the development of new medicines for asthma and COPD.

Our experience working with VirTus was terrific. They were easy to interact with, collaborative, and provided helpful advice and information at every turn throughout the clinical trial.

Brenton Scott, President and COO, Pulmotect, Inc.

Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.

Keep Updated With Our Progress

Keep up with the latest results, news and other headlines from Virtus Respiratory Research.

The email address is incorrect
Please agree to our Privacy and Policy
Something went wrong